Company
Verona Pharma
LON:VRP
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.
58 stories · page 1 of 3
Verona Pharma to present COPD drug data to leading conference
Delegates at the virtual European Respiratory Society International Congress will be provided subgroup analysis from Verona’s phase IIb trials of nebulised ensifentrine
Small Cap Feast featuring Kibo Energy, Oriole Resources, Ironridge Resources and others
What’s cooking in the IPO kitchen? Aberdeen Frontier Markets Investment Company has left AIM following a Members Voluntary Liquidation
Verona Pharma kicks off second part of phase II trial assessing potential of COPD drug used in a pressurised metered-dose inhaler
Results from the multi-dose assessment are expected in the first half of 2021
Verona Pharma primed for a busy second half
Being eagerly tracked by investors is the status of the ENHANCE phase III study of the treatment delivered using a nebuliser to people with chronic obstructive pulmonary disease
Archive
FTSE 100 gains a shade on week but closes firmly lower on Friday as China and US data disappoints
The UK's index of the largest shares closed down over 95 points on the day, or 1.55% at 6,090
Investments and investor services
Quiet Friday should allow greater attention on small caps
Delayed numbers had been expected by car dealer Lookers but this was due to a mistake on its website
Verona Pharma swims against the current with astonishing fundraise
The junior biotech saw its share price soaring following a fundraise worth double its market capitalisation. What made it so successful?
Archive
Proactive news headlines: Verona Pharma, ClearStar, Xpediator, Remote Monitored Systems …
A glance at some of the day's highlights from the Proactive Investors newswire
Verona Pharma raises US$200mln from oversubscribed private placement and subscription
The cash will be used to fund Verona’s phase III ENHANCE clinical programme for the inhaled nebulised drug, ensifentrine
Verona Pharma looks forward to phase III ensifentrine trials after US$200mln fundraise
The US authorities gave the green light to conduct the final phase of trials
Verona Pharma given US regulatory go ahead for phase III programme
The two-part programme will assess the efficacy of the company's drug ensifentrine when administered to patients with chronic obstructive pulmonary disease using a drug delivery device called a nebuliser
Verona Pharma has six abstracts accepted for industry conference and published in peer-reviewed journal
The data will be showcased at the American Thoracic Society's annual conference
Verona Pharma prepares for responses from US regulator after a busy three months
The company is focused developing discoveries such as ensifentrine for respiratory conditions such as chronic obstructive pulmonary disease
Verona Pharma phase II drug delivered “statistically significant and clinically meaningful” increases in lung function
The trial of 40 moderate to severe chronic obstructive pulmonary disease patients assessed ensifentrine’s potential when delivered via pressurised metered-dose inhalers similar to the ones used by asthmatics
Verona Pharma confident 2020 will be a transformational year
Verona is in Phase 2 development with three formulations of ensifentrine for COPD: nebulised, dry powder inhaler and pressurised metered-dose inhaler
Archive
Proactive news snapshot: Verona Pharma, SDX Energy, Europa Metals, Chesnara …
A glance at some of the day's highlights from the Proactive Investors newswire
Verona Pharma COPD trial results carried in scientific journal
Respiratory Research carried the data from Verona’s four-week, 400-patient study first released in 2018
Verona Pharma draft in two new "highly experienced" execs to lead the business into the next phase
David Zaccardelli has replaced Jan-Anders Karlsson as chief executive, while Mark Hahn has been brought in as chief financial officer